<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02956109</url>
  </required_header>
  <id_info>
    <org_study_id>18290</org_study_id>
    <secondary_id>2016-002895-29</secondary_id>
    <nct_id>NCT02956109</nct_id>
  </id_info>
  <brief_title>Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers</brief_title>
  <official_title>Relative Bioavailability Study to Investigate the Pharmacokinetics, Safety and Tolerability of Single Oral Doses of Finerenone 1.25 mg and 5 x 0.25 mg Orodispersible Tablet (Pediatric Formulation) in Comparison to 10 mg Tablet (Adult Formulation) in the Fasting Condition and to Investigate the Effect of a High Fat, High Calorie Meal on 1.25 mg Oro-dispersible Tablet in Healthy Male Subjects in a Randomized, Open-label, Four-fold Crossover Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Finerenone is developed for the treatment of diabetic kidney disease (adults) and chronic
      kidney disease (children). The purpose of the proposed trial is to test the pharmacokinetics
      of a single oral dose of finerenone (1.25 mg tablet and 5 x 0.25 mg tablets) using a novel
      orodispersible tablet formulation for the treatment of children, in comparison to the adult
      tablet formulation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2016</start_date>
  <completion_date type="Actual">March 17, 2017</completion_date>
  <primary_completion_date type="Actual">December 22, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Finerenone area under the plasma concentration vs. time curve (AUC)</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5. 3, 4, 6, 8, 12, 15 and 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Finerenone maximum plasma concentration (Cmax)</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5. 3, 4, 6, 8, 12, 15 and 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Appearance of oro-dispersible tablets assessed by questionnaire</measure>
    <time_frame>Up to 5 minutes after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Taste of oro-dispersible tablets assessed by questionnaire</measure>
    <time_frame>Up to 5 minutes after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Texture of oro-dispersible tablets assessed by questionnaire</measure>
    <time_frame>Up to 5 minutes after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Smell of oro-dispersible tablets assessed by questionnaire</measure>
    <time_frame>Up to 5 minutes after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall impression of oro-dispersible tablets assessed by questionnaire</measure>
    <time_frame>Up to 5 minutes after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Whether oro-dispersible tablets are palatable and swallowable assessed by questionnaire</measure>
    <time_frame>Up to 5 minutes after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Up to 3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Adult formulation: Finerenone tablet_Fasting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single oral dose of 10 mg finerenone tablet fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pediatric formulation: 5X 0.25 mg Finerenone ODT_Fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of 5 x 0.25 mg finerenone oro-dispersible tablets fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pediatric formulation: 1.25 mg Finerenone ODT_Fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of 1.25 mg finerenone oro-dispersible tablet fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pediatric formulation: 1.25 mg Finerenone ODT_Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of 1.25 mg finerenone oro-dispersible tablet fed; 30 minutes after start of an American breakfast</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Finerenone (BAY94-8862): 1 0mg tablet</intervention_name>
    <description>10 mg finerenone immediate-release tablet; single dose in the fasting condition</description>
    <arm_group_label>Adult formulation: Finerenone tablet_Fasting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Finerenone (BAY94-8862): 5 X 0.25 mg oro-dispersible tablets</intervention_name>
    <description>5 x 0.25 mg (1.25 mg) oro-dispersible tablets; single dose in the fasting condition</description>
    <arm_group_label>Pediatric formulation: 5X 0.25 mg Finerenone ODT_Fasting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Finerenone (BAY94-8862): 1.25 mg oro-dispersible tablet</intervention_name>
    <description>1.25 mg finerenone oro-dispersible tablets; single dose in the fasting condition or in the fed condition</description>
    <arm_group_label>Pediatric formulation: 1.25 mg Finerenone ODT_Fasting</arm_group_label>
    <arm_group_label>Pediatric formulation: 1.25 mg Finerenone ODT_Fed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects

          -  Age: 18 to 45 years (inclusive)

          -  Body mass index (BMI) : ≥ 18 and ≤ 29.9 kg/m²

          -  Race: White

        Exclusion Criteria:

          -  Subjects with conspicuous findings in medical history and pre-study examination in the
             opinion of the investigator

          -  A history of relevant diseases of vital organs, of the central nervous system or other
             organs

          -  Known renal or liver insufficiency

          -  Subjects with diagnosed malignancy, psychiatric disorders, or thyroid disorders
             (evaluated by medical history, physical examination, clinical symptoms, and assessment
             of thyroid stimulating hormone at screening)

          -  Medical disorder that would impair the subject's ability to complete the study in the
             opinion of the investigator

          -  Incompletely cured pre-existing diseases for which it can be assumed that the
             absorption, distribution, metabolism, elimination and effects of the study drugs will
             not be normal

          -  Relevant diseases within the last 4 weeks prior to the first study drug administration

          -  Smoking more than 10 cigarettes daily and/ or inability to refrain from smoking on the
             profile days until 8 h after administration

          -  Vegetarian or special diets preventing the subjects from eating the standard meals
             during the study, especially the high-fat high-calorie American breakfast or
             reluctance to ingest it
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Mönchengladbach</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41061</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2016</study_first_submitted>
  <study_first_submitted_qc>November 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2016</study_first_posted>
  <last_update_submitted>July 6, 2017</last_update_submitted>
  <last_update_submitted_qc>July 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

